Allergan (NYSE: AGN) and NephroGenex (OTCMKTS:NRXGQ) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
This is a breakdown of recent recommendations and price targets for Allergan and NephroGenex, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Allergan presently has a consensus target price of $242.31, suggesting a potential upside of 44.23%. NephroGenex has a consensus target price of $17.50, suggesting a potential upside of 624,900.00%. Given NephroGenex’s stronger consensus rating and higher probable upside, analysts clearly believe NephroGenex is more favorable than Allergan.
Valuation & Earnings